Search
for
Sort by
Research 631–660 of 1000+
- Caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and molecular dynamics
- A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis
- Palmoplantar pustulosis–like eruption following tofacitinib therapy for juvenile idiopathic arthritis
- The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
- Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia
- Successful treatment of alopecia universalis with abrocitinib: a case report
- Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients
- Topical Ruxolitinib in Combination with Oral Minoxidil Results in Hair Regrowth in a Patient with Central Centrifugal Cicatricial Alopecia and Concomitant Traction Alopecia
- Clinical Outcomes of Ritlecitinib in Treatment-Refractory Alopecia Areata: A Single-Center Real-World Study
- Delayed granulomatous eruption of the nose associated with ruxolitinib
- Effectiveness of baricitinib in severe alopecia areata in real life: a retrospective study of 87 patients.
- Abrocitinib Treatment in Diffuse Alopecia Areata: A Case Report and a Literature Review
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
- Tofacitinib Treatment in Patients With Active COVID-19 Infection
- Adjunctive Dupilumab Therapy in a Partial Responder to Baricitinib for Alopecia Areata
- Down‐regulation of Shh in the hair follicles of mice during chemotherapy‐induced hair loss is mediated by the JAK / STAT1 signaling pathway
- JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease
- Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results
- 1108 Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata
- Molecular Predictors of Ritlecitinib Efficacy in Alopecia Areata: Role of JAK3-Dependent Inflammation and Follicular Integrity
- Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Diagnosis and Management of Alopecia Areata: A Saudi Expert Consensus Statement (2023)
- Alopecia universalis successfully treated with tofacitinib
- Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review